Unicycive Therapeutics
Market cap $108M 29.2M shares (10-Q, Nov 16, 2026) × $3.70 close Nov 17, 2026
Most recent annual filing: 2026-03-30
- UNCY TDAPA corporate updateDec 31, 2026UNCY TDAPA corporate update, Dec 31, 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
UNI-494
Capital (as filed)
- Cash
- $42.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $17.0M Sep 30, 2026
- Operating cash flow
- −$7.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $59.0M cash, runway beyond 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-17 UPDATE: Unicycive Therapeutics (UNCY) - CMS Finally Spoke 🔒 Paid
- 2026-10-22 UPDATE: Unicycive Therapeutics (UNCY) - The Clock Is Set: March 25, 2027
- 2026-09-29 UPDATE: Unicycive Therapeutics (UNCY) - They Stopped Waiting for the Factory 🔒 Paid
- 2026-08-13 UPDATE: Unicycive Therapeutics (UNCY) - The Inspection Finally Got Assigned 🔒 Paid
- 2026-07-24 UPDATE: Unicycive Therapeutics (UNCY) — The Same CRL, Twice 🔒 Paid
- 2026-06-26 Unicycive Therapeutics (UNCY) - Scientific Deep Dive for Oxylanthanum Carbonate (OLC) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on Unicycive Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-26 Watch Unicycive Therapeutics (UNCY) - Scientific Deep Dive for Oxylanthanum Carbonate (OLC) and Pipeline Products OLC is a legitimate, approvable reformulation but buying common four days before a manufacturing-driven PDUFA at a 52-week high with heavy dilution and an unresolved CMS TDAPA thesis is poor risk/reward; revisit after the binary and reimbursement question de-risk.
- 2026-07-24 Avoid UPDATE: Unicycive Therapeutics (UNCY) — The Same CRL, Twice A second CRL on the same manufacturing deficiency with the FDA never having inspected the site, combined with the class-wide TDAPA window expiring December 31 2026 and post-approval financing now coming from a position of weakness, makes the commercial thesis structurally degraded.
- 2026-08-13 Avoid UPDATE: Unicycive Therapeutics (UNCY) - The Inspection Finally Got Assigned An assigned inspection converts the gating item from unschedulable to dated and binary, but the vendor has failed to clear cGMP across two review cycles, dilution is realized and permanent, and the reimbursement window keeps shrinking; the inspection result, not the assignment, is the event worth waiting for.
- 2026-09-29 Watch UPDATE: Unicycive Therapeutics (UNCY) - They Stopped Waiting for the Factory Resubmission with a new vendor carrying a clean NAI inspection record and a dated PDUFA around late March 2027 removes the main reason for AVOID, but TDAPA eligibility remains unconfirmed, the class-wide window closes before any realistic approval, and ATM dilution continues below warrant strikes.
- 2026-10-22 Watch UPDATE: Unicycive Therapeutics (UNCY) - The Clock Is Set: March 25, 2027 FDA acceptance as Class II with a March 25 2027 PDUFA confirms the timeline, but a possible pre-approval inspection of the new site is unresolved, TDAPA eligibility is unconfirmed, and the stock trades well below every warrant strike with an active ATM overhead.
- 2026-11-17 Watch UPDATE: Unicycive Therapeutics (UNCY) - CMS Finally Spoke CMS's 2027 rule narrows the TDAPA question to a single FDA NDA classification decision at approval, the original vendor has finally been inspected, and the PDUFA remains March 25 2027, but approval odds in the company's own model keep falling, ATM dilution continues below warrant strikes, and a second securities class action has been filed.
- Avoid call · opened Jul 27, 2026 at $5.13 · closed Sep 30, 2026 (downgraded to WATCH from avoid) at $4.70 · -8.5% vs XBI +4.8%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseUnicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED NOVEMBER 16, 2026→ BD updateThe Q3 10-Q lands with three items that move the UNCY thesis: the original drug-product vendor was recently inspected by the FDA (a potential timeline accelerant), CMS finalized a $12.85 per-treatment binder add to the dialysis bundle starting January 1, 2027 (restructuring the TDAPA commercial argument), and the company's own warrant model cut FDA approval odds to 57.4%–60.6% — the lowest disclosed figure to date.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseUnicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- Oct 21, 2026ReleaseUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027→ BD updateThe FDA has accepted the OLC resubmission and set a March 25, 2027 PDUFA — the exact trip-wire I flagged on September 29 — but UNCY is still trading below every warrant strike, and the TDAPA clock has ticked three more weeks closer to expiration.
- Oct 1, 2026ReleaseUnicycive Therapeutics Appoints Meredith Manning to Board of Directors
- Sep 29, 2026ReleaseUnicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate→ BD updateSummary on the 8-K
- Sep 29, 20268-KCurrent report: officer / director change, other events · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED SEPTEMBER 29, 2026→ BD updateUnicycive just resubmitted the OLC NDA — not by fixing the broken factory, but by replacing it entirely with a vendor that already carries a clean FDA inspection record and 12-month stability data. That's a materially different approval path than the one I said to avoid.
- Sep 28, 20268-KCurrent report: other events
- Sep 1, 2026ReleaseUnicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 12, 2026ReleaseUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED AUGUST 12, 2026
- Aug 12, 202610-QQuarterly report
- Jul 2, 20268-KCurrent report: other events
- Jun 30, 2026ReleaseUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)BD extracted 1 program update from this document → UNCY pipeline
- Jun 22, 2026DEFA14AProxy soliciting material
- Jun 22, 20268-KCurrent report: shareholder vote
- Jun 5, 2026S-3Shelf registration
- Jun 5, 20268-KCurrent report: material agreement
- May 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 12, 2026
- May 12, 202610-QQuarterly report
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Apr 6, 20268-KCurrent report: officer / director change
- Mar 30, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MARCH 30, 2026
- Mar 30, 202610-KAnnual report
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- Jun 15, 2026EFFECTRegistration effective
- Jun 11, 2026UPLOADUPLOAD
- Jun 11, 2026CORRESPCORRESP
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026S-8Employee plan registration
- Apr 30, 2026ARSAnnual report to shareholders